Form 4: InMed Pharma Grants Options to Senior VP Eric C. Hsu

InMed Pharmaceuticals Inc. reported the grant of 13,000 employee stock options to Senior VP Eric C. Hsu, aligning executive incentives.

Summary

• InMed Pharmaceuticals Inc. (INM) granted 13,000 employee stock options to Eric C. Hsu, Senior VP, Pre-Clinical Research/Development.
• The options have an exercise price of $1.29 per common share.
• The transaction date for this grant was December 19, 2025.
• The options will expire on December 18, 2030.
• The granted options will vest in equal monthly installments over a 36-month period, at a rate of 1/36 per month, starting from the grant date.
• Following this transaction, Eric C. Hsu beneficially owns 18,280 derivative securities (employee stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to a senior executive is generally a neutral to slightly positive event, as it aligns management incentives with shareholder interests, but does not represent a significant operational or financial milestone.

Positives

• The grant of stock options aligns the interests of Senior VP Eric C. Hsu with those of shareholders, incentivizing long-term company performance.
• The vesting schedule over 36 months acts as a retention mechanism for key management personnel.

Negatives

• The exercise of these options in the future could lead to a minor dilution of existing shareholders' equity, although the amount is relatively small.

Future Outlook

The options granted on December 19, 2025, will vest in equal monthly installments over 36 months, indicating a future alignment of executive incentives with long-term company performance.

Industry Context

This is a standard executive compensation practice in the pharmaceutical and biotechnology industries, aiming to incentivize key personnel through equity participation.

Comparison to Industry Standards

• Granting stock options to senior executives is a common practice across the biotechnology and pharmaceutical sectors, aligning management's financial interests with shareholder value creation.
• The 36-month vesting schedule is typical for executive equity grants, providing a long-term retention incentive.

Related Party Transactions

• Grant of 13,000 employee stock options to Eric C. Hsu, Senior VP, Pre-Clinical Research/Development, an insider of InMed Pharmaceuticals Inc.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon exercise, but also benefit from aligned management incentives.
• Employees (specifically Eric C. Hsu): Receives additional equity compensation, enhancing long-term financial interest in the company's success.

Next Steps

• The granted options will vest monthly over the next 36 months, starting from December 19, 2025.

Key Dates

Keywords

InMed Pharmaceuticals, INM, stock options, executive compensation, insider transaction, Form 4, equity grant, vesting schedule